Discloses use of laquinimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament formulated as a pharmaceutical oral dosage form for reducing or inhibiting progression of the level of fatigue, deterioration of functional status or deterioration of general health in a multiple sclerosis human patient who is assessed to be afflicted with fatigue, deterioration of functional status or deterioration of general health wherein laquinimod is formulated to be administered daily over a period of greater than 24 weeks. Also discloses use of laquinimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament formulated as a pharmaceutical oral dosage form for providing neuroprotection to a human subject.
